Implementation and Outcomes of a Mobile Extracorporeal Membrane Oxygenation Program in the United States During the Coronavirus Disease 2019 Pandemic.
Implementation and Outcomes of a Mobile Extracorporeal Membrane Oxygenation Program in the United States During the Coronavirus Disease 2019 Pandemic.
复制标题
DOI：
10.1053/j.jvca.2021.05.047
复制
发表时间：
2021-10
影响因子：
2.8
通讯作者：
Pollema T
中科院分区：
文献类型：
--
作者：
Odish MF;Yi C;Chicotka S;Genovese B;Golts E;Madani M;Owens RL;Pollema T
2019 年冠状病毒病 (COVID-19) 于 2020 年 3 月左右在美国开始大流行。由于作者所在地区获得体外膜肺氧合 (ECMO) 的机会有限，因此在 2020 年 4 月之前组建了一个移动 ECMO 团队，为 COVID-19 患者提供服务。评估并解决了多项后勤和运营需求，以确保项目成功，包括资格认证、设备管理和运输。一个多学科团队参与了移动 ECMO 的规划、决策和实施。从 2020 年 4 月到 2021 年 1 月，为南加州四个县 13 个机构的 22 名患者提供了移动 ECMO。接受移动 ECMO 的 COVID-19 患者出院生存率为 52.4%（21 人中的 11 人），而内部插管的类似患者的出院生存率为 45.2%（31 人中的 14 人）。移动式 ECMO 期间没有发生明显的患者或运输并发症。 ECMO 和运输团队都没有经历过严重急性呼吸综合征冠状病毒 2 的无保护暴露或感染。本文回顾了移动 ECMO 团队的实施情况，并描述了患者特征和结果。
The coronavirus disease 2019 (COVID-19) pandemic began in the United States around March 2020. Because of limited access to extracorporeal membrane oxygenation (ECMO) in the authors’ region, a mobile ECMO team was implemented by April 2020 to serve patients with COVID-19. Several logistical and operational needs were assessed and addressed to ensure a successful program, including credentialing, equipment management, and transportation. A multidisciplinary team was included in the planning, decision-making, and implementation of the mobile ECMO. From April 2020 to January 2021, mobile ECMO was provided to 22 patients in 13 facilities across four southern California counties. The survival to hospital discharge of patients with COVID-19 who received mobile ECMO was 52.4% (11 of 21) compared with 45.2% (14 of 31) for similar patients cannulated in-house. No significant patient or transportation complications occurred during mobile ECMO. Neither the ECMO nor transport teams experianced unprotected exposures to or infections with severe acute respiratory syndrome coronavirus 2. Herein, the implementation of the mobile ECMO team is reviewed, and patient characteristics and outcomes are described.
登录
查看更多内容
影响因子：
2.4
作者：
Coppola, Christopher P.;Tyree, Melissa;DiGeronimo, Robert
通讯作者：
DiGeronimo, Robert
影响因子：
4.2
作者：
Kanji, Husein D.;Chouldechova, Alexandra;Peek, Giles
通讯作者：
Peek, Giles
影响因子：
2
作者：
Illum B;Odish M;Minokadeh A;Yi C;Owens RL;Pollema T;LaBuzetta JN
通讯作者：
LaBuzetta JN
影响因子：
168.9
作者：
Peek, Giles J.;Mugford, Miranda;Elbourne, Diana
通讯作者：
Elbourne, Diana
DOI：
10.1053/j.jvca.2019.05.017
发表时间：
2019-11-01
影响因子：
2.8
作者：
Dalia, Adam A.;Axtel, Andrea;Ortoleva, Jamel
通讯作者：
Ortoleva, Jamel